The alliance's first aim is the identification, development, and validation of biomarkers of cancer and treatment response.
The test, developed with Pfizer, could identify renal cancer patients who would experience recurrence, but not who would benefit from adjuvant Sutent.
The initial FDA approval of Thermo Fisher's NGS panel test for personalizing cancer treatment may allow rapid expansion to new indications.
The so-called universal CDx approved by the FDA can gauge alterations across multiple genes associated with response to three lung cancer treatments.
In head-to-head studies, a next-generation EGFR inhibitor and an ALK inhibitor beat their older counterparts in staving of cancer progression.
Guardant will provide its Guardant360 liquid biopsy cancer assay to Pfizer's oncology business unit for use in clinical trials.
The companies will build and screen novel DNA-encoded libraries for use by Pfizer in its drug discovery efforts.
Two more papers from a former Pfizer cancer researcher have been retracted, as Retraction Watch reports.
The partners will work together to adapt a new chemical synthesis technology for DNA-encoded library creation.
The company signed separate agreements with AstraZeneca, Merck, Merck KGaA, and Pfizer to create the panel, which is expected to help speed drug development.
Using DNA to sketch crime victims might not be a great idea, the NYTimes says.
Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.
Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.
In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.